Vimarsana
Biggest News Aggregation in the World

Page 9 - Mayo Score News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mayo Score. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mayo Score Today - Breaking & Trending Today

ABIVAX: Abivax Reports 2021 Financial Results and Operations Update - Vimarsana News

ABIVAX: Abivax Reports 2021 Financial Results and Operations Update

Feedback received from the US and European regulatory agencies, both supporting the advancement ABX464 into a phase 3 clinical program in ulcerative colitis (UC), final preparations for the launch of the

Abivax reports 2021 financial results and operations update - Vimarsana News

Abivax reports 2021 financial results and operations update

Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announces its... | March 16, 2022

Maintenance of Clinical Remission Observed With Mirikizumab in UC Trial - Vimarsana News

Maintenance of Clinical Remission Observed With Mirikizumab in UC Trial

The LUCENT-2 trial evaluating mirikizumab in ulcerative colitis met the primary endpoint of clinical remission at 1 year.

Source: empr.com
Upadacitinib Shows Potential for Ulcerative Colitis - Vimarsana News

Upadacitinib Shows Potential for Ulcerative Colitis

Good efficacy and safety data provide hope for upadacitinib as an alternative JAK inhibitor for ulcerative colitis.

ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance Trial in ulcerative colitis - Vimarsana News

ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance Trial in ulcerative colitis

Impressive clinical remission in 58.4% (ITT) of 101 patients after 48 weeks of once-daily oral 50mg ABX464, showing both maintained as well as further improved efficacyFavorable safety and tolerability